Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations

Article English OPEN
Mold, Matthew ; Shardlow, Emma ; Exley, Christopher (2016)
  • Publisher: Nature Publishing Group
  • Journal: Scientific Reports, volume 6 (issn: 2045-2322, eissn: 2045-2322)
  • Related identifiers: doi: 10.1038/srep31578, pmc: PMC4981857
  • Subject: QD | Article
    mesheuropmc: complex mixtures | inorganic chemicals

Aluminium adjuvants remain the most widely used and effective adjuvants in vaccination and immunotherapy. Herein, the particle size distribution (PSD) of aluminium oxyhydroxide and aluminium hydroxyphosphate adjuvants was elucidated in attempt to correlate these properties with the biological responses observed post vaccination. Heightened solubility and potentially the generation of Al3+ in the lysosomal environment were positively correlated with an increase in cell mortality in vitro, potentially generating a greater inflammatory response at the site of simulated injection. The cellular uptake of aluminium based adjuvants (ABAs) used in clinically approved vaccinations are compared to a commonly used experimental ABA, in an in vitro THP-1 cell model. Using lumogallion as a direct-fluorescent molecular probe for aluminium, complemented with transmission electron microscopy provides further insight into the morphology of internalised particulates, driven by the physicochemical variations of the ABAs investigated. We demonstrate that not all aluminium adjuvants are equal neither in terms of their physical properties nor their biological reactivity and potential toxicities both at the injection site and beyond. High loading of aluminium oxyhydroxide in the cytoplasm of THP-1 cells without immediate cytotoxicity might predispose this form of aluminium adjuvant to its subsequent transport throughout the body including access to the brain.
  • References (42)
    42 references, page 1 of 5

    1. Gupta, A., Das, S., Schanen, B. & Seal, S. Adjuvants in micro- to nanoscale: current state and future direction. Nanomed. Nanobiotechnol. 8, 61-84 (2016).

    2. Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597-1608 (2013).

    3. Oleszycka, E. et al. IL-1α and inflammasome-independent IL-1β promote neutrophil infiltration following alum vaccination. FEBS J. 283, 9-24 (2016).

    4. Exley, C., Siesjö, P. & Eriksson, H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 30, 103-109 (2010).

    5. Shaw, C. A. & Petrik, M. S. Aluminum hydroxide injections lead to motor decfiits and motor neuron degeneration. J. Inorg. Biochem . 103, 1555-1562 (2009).

    6. Tomljenovic, L. & Shaw, C. A. Mechanisms of aluminium adjuvant toxicity and autoimmunity in paediatric populations. Lupus. 21, 223-230 (2012).

    7. Shoenfeld, Y. & Agmon-Levin, N. 'ASIA'-Autoimmune/inflammatory syndrome inducedby adjuvants. J. Autoimmun. 36, 4-8 (2011).

    8. Lindblad, E. B. Aluminium compounds for use in vaccines. Immunol. Cell Biol. 82, 497-505 (2004).

    9. Lee, H. S. Detection of papillomavirus (HPV) L1 gene DNA possibly bound to particulate aluminium adjuvant in the HPV vaccine Gardasil®. J. Inorg. Biochem. 117, 85-92 (2012).

    10. Ghimire, T. R. eTh mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm. SpringerPlus. 4:181 (2015).

  • Metrics
    No metrics available
Share - Bookmark